Condition (MeSH)
Optic Atrophy, Autosomal Dominant
ClinicalTrials.gov lists 8 trials for Optic Atrophy, Autosomal Dominant or a narrower condition beneath it. PYC Therapeutics has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
8 of the 8 trials are tagged with Optic Atrophy, Autosomal Dominant itself; the rest are tagged with a narrower condition beneath it.
When did Optic Atrophy, Autosomal Dominant trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 2 |
| 2016 | 1 |
| 2011 | 1 |
| 2010 | 1 |
| 2008 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Optic Atrophy, Autosomal Dominant trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Not applicable | 2 |
| Observational | 4 |
How many Optic Atrophy, Autosomal Dominant trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Completed | 1 |
| Terminated | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Optic Atrophy, Autosomal Dominant trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| PYC Therapeutics | 3 |
| MD Stem Cells | 1 |
| Okuvision GmbH | 1 |
Which publications cover Optic Atrophy, Autosomal Dominant? (8)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Induced Pluripotent Stem Cells for Inherited Optic Neuropathies-Disease Modeling and Therapeutic Development. | Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society | 2022 | Yes |
| Mutations in SLC25A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorder. | Nature genetics | 2015 | Yes |
| Macular sensitivity and fixation patterns in patients with autosomal dominant optic atrophy. | Danish medical journal | 2014 | Yes |
| Down-regulation of OPA1 alters mouse mitochondrial morphology, PTP function, and cardiac adaptation to pressure overload. | Cardiovascular research | 2012 | Yes |
| Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies. | Progress in retinal and eye research | 2011 | Yes |
Showing 5 of 8 publications.
Prevalence (12)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Autosomal dominant optic atrophy | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Autosomal dominant optic atrophy | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Unspecified |
| Autosomal dominant optic atrophy | Point prevalence | 1-9 / 100 000 | United Kingdom | GB | Exact |
| Autosomal dominant optic atrophy | Point prevalence | 1-9 / 100 000 | Worldwide | Not stated | Unspecified |
| Autosomal dominant optic atrophy | Point prevalence | 1-5 / 10 000 | Denmark | Not stated | Exact |
Showing 5 of 12 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Autosomal dominant optic atrophy | 98672 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Autosomal dominant optic atrophy | 98672 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.